Biopharma Competition Leads Physicians 
PM360
APRIL 22, 2024
From important changes to engaging physicians to finding out how new technologies will help address HCPs education needs, hear what our specialist had to say. What do you think are the most important changes to engaging physicians our industry needs to keep in mind now?
The Marketing Advantage
MAY 8, 2023
Lack of Data and/or Proxies There is typically little to no competitive data available With over 95% of the over 7,000 estimated rare diseases having no treatment, these products typically have no competition and thus no competitive data. Additionally, though claims data, ICD-11 codes, patient advocacy groups, etc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
OCTOBER 25, 2023
Unlike in Part D, Part B drugs are physician administered and there is less certainty regarding which drugs will be tapped for negotiations (i.e., exclusions exist for orphan drug designation and biosimilar competition ). Nonetheless, Clarivate expects the initial list to include oncology treatments KEYTRUDA® and OPDIVO®.
Clarivate
APRIL 18, 2024
Humana is following a similar growth strategy as it sharpens competition with UnitedHealthcare in the Medicare Advantage sector. As a lead healthcare research and data analyst, she analyses the Texas and Georgia healthcare markets and tracks the rapidly evolving convenient care industry.
Clarivate
APRIL 24, 2023
CVS then began affiliating with health systems across the country (like Cleveland Clinic ) for physician oversight of MinuteClinic’s staffed midlevel providers, just as Walgreens was rising as a formidable competitor in the convenient care space through its own walk-in clinics that it launched in fall 2006.
Clarivate
DECEMBER 6, 2022
In a fiercely competitive U.S. While marquee IDNs attract national headlines, these smaller systems reflect how markets are adjusting to an increasingly value-based and competitive landscape. ChristianaCare’s future expansion plans could escalate the competition between Highmark and UPMC. ChristianaCare, Wilmington, Delaware.
Clarivate
OCTOBER 10, 2022
Fruquintinib will face fierce competition should it be approved in the third- and later-line setting. The question of which KRAS inhibitor is most effective remains elusive, although being first to market in addition to strong efficacy and safety data could differentiate the more competitive agent. Key ESMO findings. months vs. 20.3
Expert insights. Personalized for you.
59 
Let's personalize your content